Procter Gamble Health Stock Cash And Equivalents
| PGHL Stock | 5,299 159.20 3.10% |
Procter Gamble Health fundamentals help investors to digest information that contributes to Procter Gamble's financial success or failures. It also enables traders to predict the movement of Procter Stock. The fundamental analysis module provides a way to measure Procter Gamble's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Procter Gamble stock.
| Last Reported | Projected for Next Year | ||
| Cash And Equivalents | 3.1 B | 3.7 B |
Procter | Cash And Equivalents |
Procter Gamble Health Company Cash And Equivalents Analysis
Procter Gamble's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Procter Gamble Cash And Equivalents | 3.4 B |
Most of Procter Gamble's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Procter Gamble Health is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Procter Gamble Health has 3.4 B in Cash And Equivalents. This is 313.74% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all India stocks is 25.69% lower than that of the firm.
Procter Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Procter Gamble's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Procter Gamble could also be used in its relative valuation, which is a method of valuing Procter Gamble by comparing valuation metrics of similar companies.Procter Gamble is currently under evaluation in cash and equivalents category among its peers.
Procter Fundamentals
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 85.75 B | ||||
| Shares Outstanding | 16.6 M | ||||
| Shares Owned By Insiders | 52.17 % | ||||
| Shares Owned By Institutions | 16.53 % | ||||
| Price To Book | 16.34 X | ||||
| Price To Sales | 7.45 X | ||||
| Revenue | 11.51 B | ||||
| Gross Profit | 8.68 B | ||||
| EBITDA | 3.07 B | ||||
| Net Income | 2.01 B | ||||
| Cash And Equivalents | 3.4 B | ||||
| Total Debt | 95.6 M | ||||
| Book Value Per Share | 324.29 X | ||||
| Cash Flow From Operations | 2.28 B | ||||
| Earnings Per Share | 131.41 X | ||||
| Beta | 0.51 | ||||
| Market Capitalization | 86.42 B | ||||
| Total Asset | 7.94 B | ||||
| Retained Earnings | 3.71 B | ||||
| Working Capital | 3.05 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 7.94 B |
About Procter Gamble Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Procter Gamble Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Procter Gamble using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Procter Gamble Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Procter Stock Analysis
When running Procter Gamble's price analysis, check to measure Procter Gamble's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procter Gamble is operating at the current time. Most of Procter Gamble's value examination focuses on studying past and present price action to predict the probability of Procter Gamble's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procter Gamble's price. Additionally, you may evaluate how the addition of Procter Gamble to your portfolios can decrease your overall portfolio volatility.